Evidence map›Paper›PMID 41778233›Full record

ArticleCancer diagnosis & prognosis

Pre-treatment NLR and Changes in NLR Are Associated With Survival Following the Initiation of Immune Checkpoint Inhibitor Therapy in Patients With Non-small Cell Lung Cancer.

Minehiko Inomata, Yuki Matsushiro, Yuki Tanabe, Moe Hashizume, Kenji Azechi, Nozomu Murayama, Naoki Takata, Zenta Seto, Kotaro Tokui, Seisuke Okazawa and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Minehiko InomataFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Yuki MatsushiroFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Yuki TanabeFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Moe HashizumeFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kenji AzechiFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Nozomu MurayamaFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Naoki TakataFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Zenta SetoFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kotaro TokuiFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Seisuke OkazawaFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Shingo ImanishiFirst Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Ryuji HayashiDepartment of Medical Oncology and Palliative Medicine, Toyama University Hospital, Toyama, Japan.
Mosaburo KainumaDepartment of Japanese Oriental Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: The pre-treatment neutrophil/lymphocyte ratio (NLR) has been associated with survival after the initiation of immune checkpoint inhibitor (ICI) therapy. However, information regarding a change in NLR after ICI therapy is scarce. We conducted this retrospective study to investigate the association between a change in NLR and outcomes in patients with non-small cell lung cancer (NSCLC) who were treated with ICI therapy. Patients and Methods: Data on patients with NSCLC who were treated with ICI therapy, including PD-1/PD-L1 antibody monotherapy and combination therapy with cytotoxic agents or CTLA-4 antibody between 2017 and 2023, were analyzed. Pre-treatment NLR and the change in NLR following treatment initiation were evaluated. Pre-treatment NLR was measured within 14 days before the day of treatment initiation and compared with that measured 56 days (±14 days) after treatment initiation. Results: A total of 121 patients were included in the study. The Cox proportional hazards model revealed that a pre-treatment NLR of ≥5 ( Conclusion: Pre-treatment NLR and a change in NLR were associated with progression-free survival after the initiation of ICI therapy. Furthermore, concomitant use of cytotoxic agents and liver metastases may be associated with a change in NLR.

Indexed as

Immune checkpoint inhibitorimmunogenic cell deathlung cancerneutrophil/lymphocyte ratioprognosis

Identifiers

PMID41778233
PMCPMC12951381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.